Rosenblat JD

Psilocybin.

Rosenblat JD, Husain MI

The effect of ketamine on mitochondrial bioenergetics, viability, and function: A systematic review.

Wong S, Le GH, Selby S +7

Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression: A Randomized Clinical Trial.

Orsini DK, Di Luch S, Tomlinson G +18

Psychedelics Trials and Outcomes-A Closer Look.

Carhart-Harris RL, Rosenblat JD

Ketamine assisted psychotherapy to reduce chronic neuropathic pain: A mixed-methods randomized pilot trial.

Goel A, Diep C, Zahin A +16

Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.

Orsini DK, Wong S, Di Luch S +15

Evaluating the abuse liability of ketamine in the treatment of mood disorders: A systematic review.

Vasudeva S, Lovell GFM, Wong S +5

ArticleMDMA

The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression.

Le GH, Wong S, Johnson DE +6

Esketamine for major depressive disorder: pharmacokinetics and toxicological considerations.

Vasudeva S, Lovell GFM, Rosenblat JD

Measuring and appraising placebo effects in clinical trials: contemporary challenges and approaches in psychiatry.

Taylor JJ, Szigeti B, Silverberg ND +11

Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review.

Lovell GFM, Vasudeva S, Orsini DK +6

Psychedelics as a potential treatment for borderline personality disorder: A narrative review.

Artna E, Sandhu G, Chisamore N +5

Changes over time in hallucinogen-related emergency department visits in Ontario, Canada.

Myran DT, MacDonald-Spracklin R, Levesque AR +7

The combination of exercise and psychedelics for the treatment of major depressive disorder.

Fabiano N, Stubbs B, Lawrence DW +5

The effect of glutamatergic modulators on sleep behavior and architecture in depressive disorders: A systematic review.

Valentino K, Ballum H, Cheung W +11

Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression.

Kaczmarek ES, Rodrigues NB, Chisamore N +8

Progress, potential and pitfalls of ketamine as a treatment for depression.

Orsini DK, Di Luch S, Lovell GFM +1

Early response to psilocybin in adults with treatment-resistant depression as a predictor for antidepressant efficacy.

Doyle Z, Chisamore N, Kaczmarek ES +9

A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals?

Le GH, Wong S, Johnson DE +6

Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trial.

Johnson DE, Meshkat S, Kaczmarek ES +11

ArticleMDMA

Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.

Højlund M, Kafali HY, Kırmızı B +33

A Systematic Review of the Effects of N-Methyl-D-Aspartate Receptor Antagonists on Pancreatic Islets.

Wong S, Le GH, Uhlig J +5

Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review.

Wong S, Jones BDM, Thiyagarajah MT +10

Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal.

Sabbah SG, Li S, Wong S +5

Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis.

Wong S, Meckling G, Fabiano N +11

Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials.

Kittur ME, Burgos M LA, Jones BDM +4

A Global Population-Based Study on the Association Between Ketamine and Esketamine With Suicidality Using WHO VigiBase.

Kwan ATH, Lakhani M, Rosenblat JD +8

Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression.

Brudner RM, Kaczmarek E, Blainey MG +9

Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review.

Chen MJQ, Chen-Li D, Chisamore N +7

Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude.

Chisamore N, Kaczmarek ES, Doyle Z +8

Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population.

Myran DT, Xiao J, Fabiano N +8

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder.

Meshkat S, Kaczmarek E, Doyle Z +7

Hepatic adverse events associated with ketamine and esketamine: A population-based disproportionality analysis.

Kwan ATH, Lakhani M, Teopiz KM +8

Functional Connectivity Between Glutamate Receptor Antagonism and Insulin Pathways: Implications for Modeling Mechanism of Action of Ketamine/Esketamine and Dextromethorphan in Depression Treatment.

Wong S, Le GH, Mansur RB +2

A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.

Kwan ATH, Rosenblat JD, Mansur RB +7

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression.

Poulin JM, Bigford GE, Lanctôt KL +13

The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS).

McIntyre RS, Mansur RB, Rosenblat JD +2

Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.

Chisamore N, Johnson D, Chen MJQ +6

The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).

Kwan ATH, Rosenblat JD, Mansur RB +2

Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis.

Calder CN, Kwan ATH, Teopiz KM +7

Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.

Le GH, Wong S, Badulescu S +11

A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.

Wong S, Kwan ATH, Teopiz KM +8

The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.

d'Andrea G, Pettorruso M, Di Lorenzo G +16

Augmentation in depression: Esketamine, a new standard?

Rosenblat JD, McIntyre RS

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.

Haikazian S, Chen-Li DCJ, Johnson DE +6

Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.

McIntyre RS, Alsuwaidan M, Baune BT +24

Ketamine for bipolar depression: an updated systematic review.

Fancy F, Haikazian S, Johnson DE +5

Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.

Wong S, Yu AY, Fabiano N +7

Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).

Pettorruso M, Guidotti R, d'Andrea G +25

Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial.

Husain MI, Blumberger DM, Castle DJ +8

Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects.

Rosenblat JD, Leon-Carlyle M, Ali S +2

Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?

Husain MI, Ledwos N, Fellows E +5

A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study).

Rosenblat JD, deVries FE, Doyle Z +9

A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.

Ledwos N, Rosenblat JD, Blumberger DM +4

A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.

Pouyan N, Halvaei Khankahdani Z, Younesi Sisi F +14

The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.

Rosenblat JD, Husain MI, Lee Y +18

Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.

Ling S, Ceban F, Lui LMW +12

Registered clinical studies investigating psychedelic drugs for psychiatric disorders.

Siegel AN, Meshkat S, Benitah K +6

Europe PMC2021